Navamedic Asa · OSL:NAVA
Navamedic Asa — Q3 2022 Earnings Presentation
24 slides from Navamedic Asa's earnings presentation, Nov 1, 2022
Slide 1: Third quarter 2022 results
Q3 2022 Third quarter 2022 results Navamedic ASA 1 November 2022 Kathrine Gamborg Andreassen, CEO Lars Hjarrand, CFO
Slide 2: Growth continues
Growth continues Another quarter with solid revenues and EBITDA Solid growth achieved across the portfolio Obesity Continued strong demand for Mysimba® REVENUE GROSS MARGIN EBITDA Q3 92.8 MNOK 42.5% 12.7 MNOK Further strengthened footprint in obesity with acquisition of 2022 Up 46% YoY 38.9% in Q3 2
Slide 3: On track towards 20% organic Y/Y revenue growth target
On track towards 20% organic Y/Y revenue growth target Continued positive trend in revenue and EBITDA +46% Consistent strong revenue 350 35% growth over time driven by positive market trends, 300 30% successful build-up of new categories, M&A and 250 25% distribution partnerships Normal fluctuation
Slide 4: Navamedic in brief
Navamedic in brief Nordic pharma company targeting growth in Northern Europe A reliable supplier of high- Presence and sales in all Strong local competence Ambitious growth quality pharma products, Nordic countries, Benelux, in regulatory, strategy, high-potential within consumer health, the Baltics
Slide 5: Ambition to build a NOK 1 bn revenue company
Ambition to build a NOK 1 bn revenue company STRATEGY STRENGTHEN THE CORE 1 Untapping the potential within existing products and territories. Ongoing negotiations for attractive new agreements. SECURE AND INCREASE THE VALUE THROUGH 2 OWNERSHIP Innovative pipeline for in-licensing of new RX or OTC, i
Slide 6: High-quality portfolio with several hero products
High-quality portfolio with several hero products MEDICAL NUTRITION SPECIALTY PHARMA CONSUMER HEALTH BRANDED GENERICS Medical nutrition products for Obesity & urology Gastro, pain, urology & other Antibiotics, cardiology, generics treatment of IEM* and weight loss 52,4 40,3 63,3 37% 110,2 59% 30% 28
Slide 7: Medical Nutrition
Medical Nutrition Stable growth continues – driven by Modifast • Sales of Modifast Q3 2022 REVENUE supporting continued growth in the category 21.6 MNOK • Modifast product range to (Q3 2021: 12.9 MNOK) be updated with new formula and packaging in Q4 7
Slide 8: Specialty Pharma
Specialty Pharma Strong growth in obesity CONTINUED STRONG MYSIMBA WHOLESALE DEVELOPMENT • Key product category for Q3 2022 REVENUE Navamedic with solid growth MNOK expected going forward 140 34.9 MNOK • Increased production 120 100 capacity going forward, with (Q3 2021: 22.3 MNOK) new packaging lin
Slide 9: Consumer Health
Consumer Health Gastro category developing strongly, continued strong potential for Navamedic going forward • Successful launch of ForlaxGo in Q3 2022 REVENUE Norway and Sweden 14.9 MNOK • Alflorex® and Gelorevoice ® have delivered solid growth in the (Q3 2021: 11.5 MNOK) quarter • Absolut Tørr has
Slide 10: Branded Generics
Branded Generics Antibiotics portfolio with solid growth • Long-term tenders secured for the antibiotic's portfolio Q3 2022 REVENUE • Providing increased 21.6 MNOK revenue visibility (Q3 2021: 16.9 MNOK) • Sales of the antibiotics portfolio near doubled in the quarter compared to Q3 last year 10
Slide 11: Financials
FINANCIALS @ Navamedic
Slide 12: Key consolidated profit and loss figures
Financials Key consolidated profit and loss figures In Q3 2022, revenues grew by 46% (in NOK '1000) Q3 2022 Q3 2021 YTD 2022 YTD 2021 FY 2021 compared to the same quarter last year Operating revenues 92 811 63 620 266 168 188 279 278 439 Gross profit 39 453 24 768 113 757 73 947 111 744 Gross Profit
Slide 13: Assets
Financials Assets The increase in Goodwill is due to the (in NOK '1000) 30.09.2022 30.09.2021 31.12.2021 Impolin acquisition but is unchanged during Goodwill 98 771 62 288 61 031 the quarter Deferred tax assets 9 168 9 168 9 168 Other intangible assets 32 593 28 773 27 342 Shares in associated compa
Slide 14: Equity and liabilities
Financials Equity and liabilities (in NOK '1000) 30.09.2022 30.09.2021 31.12.2021 Equity ratio of 48.5% Total equity 188 699 147 566 151 237 Non-current license liabilities 6 198 8 752 8 171 The increase in Loans and borrowings Loans and borrowings 53 411 19 994 38 980 is due to the financing of the
Slide 15: Cash flow Group – total operations
Financials Cash flow Group – total operations (in NOK '1000) Q3 2022 Q3 2021 YTD 2022 YTD 2021 FY 2021 The cash flow from Operating Activities is mainly the result of Net profit coupled Net cash flow from operating activities 11 148 4 172 -1 987 -12 585 -1 300 with changes in net working capital. Ne
Slide 16: Summary & Outlook
SUMMARY & OUTLOOK 16 @ Navamedic
Slide 17: Summary and outlook
Navamedic ASA Summary and outlook We are building a leading Nordic pharma company targeting growth in Northern Europe TARGETS AND AMBITIONS On track to reach growth target 20% annual organic • Solid growth achieved across the entire portfolio growth • Continued to strengthen the core by driving unde
Slide 18: Q&A
Q&A @ Navamedic
Slide 19: Thank you for your attention!
Thank you for your attention! Navamedic’s Q4 2022 presentation will be held on February 16, 2023 19
Slide 20: Appendix
APPENDIX @ Navamedic
Slide 21: Condensed consolidated statement of comprehensive income
Navamedic ASA Condensed consolidated statement of comprehensive income (in NOK '1000) Q3 2022 Q3 2021 YTD 2022 YTD 2021 FY 2021 Operating revenues 92 811 63 620 266 168 188 279 278 439 Total revenue 92 811 63 620 266 168 188 279 278 439 Cost of materials -53 358 -38 852 -152 411 -114 332 -166 695 Gr
Slide 22: Condensed consolidated statement of cash flows
Navamedic ASA Condensed consolidated statement of cash flows (in NOK '1000) Q3 2022 Q3 2021 YTD 2022 YTD 2021 FY 2021 Cash flow from operating activities Profit before tax 5 244 342 15 340 379 2 358 Adjusted for: Depreciation, amortization and impairment 1 782 1 430 5 442 4 152 6 716 Financial incom
Slide 23: Basis for preparation and APM definitions
Appendix Basis for preparation This presentation provides financial highlights for the quarter for Navamedic Group. The financial information is not reported according to the requirements in IAS 34 (Interim Financial Reporting) and the figures are not audited. The same measurement principles as pres
Slide 24: Copyright and disclaimer
Appendix Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Navamedic and third party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be reproduced in any